Turn Therapeutics Names Experienced Capital Markets Leader Andrew Scott as VP of Corporate Communications
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Source: Newsfilter
New Executive Appointment: Turn Therapeutics Inc. has appointed Andrew Scott as Vice President of Corporate Communications to oversee investor relations and corporate communications as the company enters a new growth phase following its public listing.
Experience and Background: Andrew Scott brings over 30 years of experience in capital markets and corporate finance, previously serving as Managing Director at ThinkEquity LLC and Vice President at Fortress Biosciences, where he helped raise approximately $3 billion in the life sciences sector.
Company Overview: Turn Therapeutics is focused on developing and commercializing products for dermatology, wound care, and infectious diseases, with three FDA clearances and ongoing late-stage clinical programs in eczema and onychomycosis.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and potential risks associated with its development programs and strategic plans, emphasizing the uncertainties involved.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TTRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TTRX
Wall Street analysts forecast TTRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.200
Low
6.15
Averages
6.77
High
8.00
Current: 5.200
Low
6.15
Averages
6.77
High
8.00
About TTRX
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Turn Therapeutics Announces Interim Results of GX-03 Trial for Eczema
- Clinical Trial Progress: Turn Therapeutics' ongoing Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis enrolled 50 patients in a randomized, double-blind study, revealing that 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity within four weeks, significantly higher than the 65.2% in the control group.
- Significant Efficacy Improvement: At Week 4, 44.4% of the GX-03 group reached the EASI-90 improvement standard, compared to 30.4% in the control group, with this rate increasing to 51.9% versus 34.8% by Week 8, demonstrating the drug's rapid and sustained efficacy.
- Good Safety Profile: No treatment-related serious adverse events were reported during the trial, and tolerability was consistent across groups, indicating a favorable safety profile for GX-03 and enhancing its potential as a localized treatment option.
- Future Plans: Turn Therapeutics plans to present detailed results at the Jefferies Global Healthcare conference on June 4, 2026, further advancing the clinical development of GX-03 to provide new treatment options for patients with moderate-to-severe atopic dermatitis.
See More
Turn Therapeutics Stock Rises 20% on Positive Trial Results
- Clinical Trial Results: Turn Therapeutics Inc. (TTRX) reported that 92.6% of subjects in its phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis achieved a 50% reduction in eczema severity within four weeks, leading to a stock price increase of over 20%, indicating strong market potential for the drug.
- Optimization Strategy Implementation: The company is refining its trial strategy based on interim analysis results by adjusting enrollment criteria to balance baseline disease severity and body surface area, which is expected to enhance the likelihood of success in subsequent phases and boost investor confidence.
- New Product Development: Conexeu Sciences Inc. (CNXU) saw its stock rise over 18% following its Nasdaq listing, as it launched the B.R.E.A.S.T. bioprinting project, marking a strategic entry into multi-billion-dollar markets, with plans to submit a 510(k) application in early 2027, advancing the product towards clinical trials.
- Strategic Transformation: LIXTE Biotechnology Holdings Inc. (LIXT) announced a shift towards an AI energy infrastructure equipment and services platform, resulting in a stock price increase of over 15%, which not only addresses the rapidly growing power demands in North America but also seeks a strategic partner for its clinical-stage pharmaceutical operations, showcasing a diversified future direction for the company.
See More
Interim Analysis Results of GX-03 Clinical Trial
- Significant Efficacy: Among subjects treated with GX-03, 92.6% achieved a 50% reduction in eczema severity within 4 weeks (EASI-50), compared to 65.2% in the control group, highlighting GX-03's substantial advantage in skin disease improvement and potential for future market introduction.
- Enhanced Deep Response: 44.4% of GX-03 subjects achieved a 90% reduction in eczema severity (EASI-90) at 4 weeks, versus 30.4% in the control group, with this increasing to 51.9% by week 8, indicating GX-03's potential for sustained and deeper therapeutic effects that could influence clinical treatment strategies.
- Good Safety Profile: No treatment-related serious adverse events or tolerability issues were observed during the interim analysis, demonstrating GX-03's favorable safety and tolerability, which is crucial for future regulatory approvals and patient acceptance.
- Trial Strategy Optimization: The company plans to refine enrollment criteria and endpoint selection based on interim findings to better control baseline EASI and body surface area involvement, ensuring the reliability and effectiveness of trial results, thereby enhancing GX-03's market competitiveness.
See More
Turn Therapeutics Appoints Dr. Hahn to Advance GX-03 Development
- Expert Appointment: Turn Therapeutics has appointed Dr. Stephen M. Hahn, former FDA Commissioner, to oversee the clinical and regulatory strategy for GX-03, aiming to advance the drug's clinical trials for moderate-to-severe atopic dermatitis and enhance the company's competitive edge in the biotech sector.
- GX-03's Therapeutic Potential: GX-03 is a first-in-class, non-systemic topical cytokine-modulating therapy designed for moderate-to-severe atopic dermatitis, expected to provide a more effective localized treatment option by modulating IL-36, IL-4, IL-13, and IL-31 signaling pathways, addressing urgent patient needs.
- Dr. Hahn's Background: With extensive experience in clinical and regulatory affairs during his tenure at the FDA, where he oversaw both COVID and non-COVID regulatory activities, Dr. Hahn is well-positioned to provide strategic guidance to Turn Therapeutics, helping the company navigate the complexities of the biotech landscape.
- Future Outlook: Currently in a Phase 2 randomized controlled trial, GX-03 is expected to release topline results in mid-2026, and if successful, it will offer new treatment options for atopic dermatitis patients, further solidifying Turn Therapeutics' position in the market.
See More
Turn Therapeutics Reports FY EPS Beat and Secures Financing
- Earnings Performance: Turn Therapeutics reported a FY GAAP EPS of -$0.12, beating expectations by $0.01, indicating some improvement in financial management despite still being in a loss position.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $5.08 million, excluding the $7.0 million in gross proceeds from the financing agreement with Avenue Capital, suggesting potential enhancement in liquidity.
- Financing Support: Turn Therapeutics secured up to $25 million in financing from Avenue Capital Group, which will be utilized to support the company's R&D and operations, thereby strengthening its competitive position in the market.
- Historical Financial Data: Historical earnings data for Turn Therapeutics indicates that despite facing challenges, the company is actively working to improve its financial performance and seeking new growth opportunities.
See More
Turn Therapeutics Secures $25 Million Growth Capital Loan
- Loan Agreement Established: Turn Therapeutics has entered into a growth capital loan facility with Avenue Capital Group for up to $25 million, including an initial $7 million tranche, which is expected to provide essential funding to support the company's research and development efforts.
- Clear Funding Purpose: The initial funds will be utilized to support Turn Therapeutics' Phase 2 clinical trial for atopic dermatitis and prepare for registrational trials for GX-03, thereby enhancing its market competitiveness in dermatological treatments.
- Milestone-Driven Financing: An additional $18 million will be available based on the achievement of clinical and corporate milestones, a structure that not only incentivizes the company to meet key objectives but also provides flexibility for future funding needs.
- Optimistic Financial Outlook: The company anticipates that this financing will extend its runway through the end of 2027, ensuring continued operations during critical clinical trial phases and laying a solid foundation for future growth.
See More
Turn Therapeutics Announces Interim Results of GX-03 Trial for Eczema
- Clinical Trial Progress: Turn Therapeutics' ongoing Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis enrolled 50 patients in a randomized, double-blind study, revealing that 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity within four weeks, significantly higher than the 65.2% in the control group.
- Significant Efficacy Improvement: At Week 4, 44.4% of the GX-03 group reached the EASI-90 improvement standard, compared to 30.4% in the control group, with this rate increasing to 51.9% versus 34.8% by Week 8, demonstrating the drug's rapid and sustained efficacy.
- Good Safety Profile: No treatment-related serious adverse events were reported during the trial, and tolerability was consistent across groups, indicating a favorable safety profile for GX-03 and enhancing its potential as a localized treatment option.
- Future Plans: Turn Therapeutics plans to present detailed results at the Jefferies Global Healthcare conference on June 4, 2026, further advancing the clinical development of GX-03 to provide new treatment options for patients with moderate-to-severe atopic dermatitis.
See More
Turn Therapeutics Stock Rises 20% on Positive Trial Results
- Clinical Trial Results: Turn Therapeutics Inc. (TTRX) reported that 92.6% of subjects in its phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis achieved a 50% reduction in eczema severity within four weeks, leading to a stock price increase of over 20%, indicating strong market potential for the drug.
- Optimization Strategy Implementation: The company is refining its trial strategy based on interim analysis results by adjusting enrollment criteria to balance baseline disease severity and body surface area, which is expected to enhance the likelihood of success in subsequent phases and boost investor confidence.
- New Product Development: Conexeu Sciences Inc. (CNXU) saw its stock rise over 18% following its Nasdaq listing, as it launched the B.R.E.A.S.T. bioprinting project, marking a strategic entry into multi-billion-dollar markets, with plans to submit a 510(k) application in early 2027, advancing the product towards clinical trials.
- Strategic Transformation: LIXTE Biotechnology Holdings Inc. (LIXT) announced a shift towards an AI energy infrastructure equipment and services platform, resulting in a stock price increase of over 15%, which not only addresses the rapidly growing power demands in North America but also seeks a strategic partner for its clinical-stage pharmaceutical operations, showcasing a diversified future direction for the company.
See More
Interim Analysis Results of GX-03 Clinical Trial
- Significant Efficacy: Among subjects treated with GX-03, 92.6% achieved a 50% reduction in eczema severity within 4 weeks (EASI-50), compared to 65.2% in the control group, highlighting GX-03's substantial advantage in skin disease improvement and potential for future market introduction.
- Enhanced Deep Response: 44.4% of GX-03 subjects achieved a 90% reduction in eczema severity (EASI-90) at 4 weeks, versus 30.4% in the control group, with this increasing to 51.9% by week 8, indicating GX-03's potential for sustained and deeper therapeutic effects that could influence clinical treatment strategies.
- Good Safety Profile: No treatment-related serious adverse events or tolerability issues were observed during the interim analysis, demonstrating GX-03's favorable safety and tolerability, which is crucial for future regulatory approvals and patient acceptance.
- Trial Strategy Optimization: The company plans to refine enrollment criteria and endpoint selection based on interim findings to better control baseline EASI and body surface area involvement, ensuring the reliability and effectiveness of trial results, thereby enhancing GX-03's market competitiveness.
See More
Turn Therapeutics Appoints Dr. Hahn to Advance GX-03 Development
- Expert Appointment: Turn Therapeutics has appointed Dr. Stephen M. Hahn, former FDA Commissioner, to oversee the clinical and regulatory strategy for GX-03, aiming to advance the drug's clinical trials for moderate-to-severe atopic dermatitis and enhance the company's competitive edge in the biotech sector.
- GX-03's Therapeutic Potential: GX-03 is a first-in-class, non-systemic topical cytokine-modulating therapy designed for moderate-to-severe atopic dermatitis, expected to provide a more effective localized treatment option by modulating IL-36, IL-4, IL-13, and IL-31 signaling pathways, addressing urgent patient needs.
- Dr. Hahn's Background: With extensive experience in clinical and regulatory affairs during his tenure at the FDA, where he oversaw both COVID and non-COVID regulatory activities, Dr. Hahn is well-positioned to provide strategic guidance to Turn Therapeutics, helping the company navigate the complexities of the biotech landscape.
- Future Outlook: Currently in a Phase 2 randomized controlled trial, GX-03 is expected to release topline results in mid-2026, and if successful, it will offer new treatment options for atopic dermatitis patients, further solidifying Turn Therapeutics' position in the market.
See More
Turn Therapeutics Reports FY EPS Beat and Secures Financing
- Earnings Performance: Turn Therapeutics reported a FY GAAP EPS of -$0.12, beating expectations by $0.01, indicating some improvement in financial management despite still being in a loss position.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $5.08 million, excluding the $7.0 million in gross proceeds from the financing agreement with Avenue Capital, suggesting potential enhancement in liquidity.
- Financing Support: Turn Therapeutics secured up to $25 million in financing from Avenue Capital Group, which will be utilized to support the company's R&D and operations, thereby strengthening its competitive position in the market.
- Historical Financial Data: Historical earnings data for Turn Therapeutics indicates that despite facing challenges, the company is actively working to improve its financial performance and seeking new growth opportunities.
See More
Turn Therapeutics Secures $25 Million Growth Capital Loan
- Loan Agreement Established: Turn Therapeutics has entered into a growth capital loan facility with Avenue Capital Group for up to $25 million, including an initial $7 million tranche, which is expected to provide essential funding to support the company's research and development efforts.
- Clear Funding Purpose: The initial funds will be utilized to support Turn Therapeutics' Phase 2 clinical trial for atopic dermatitis and prepare for registrational trials for GX-03, thereby enhancing its market competitiveness in dermatological treatments.
- Milestone-Driven Financing: An additional $18 million will be available based on the achievement of clinical and corporate milestones, a structure that not only incentivizes the company to meet key objectives but also provides flexibility for future funding needs.
- Optimistic Financial Outlook: The company anticipates that this financing will extend its runway through the end of 2027, ensuring continued operations during critical clinical trial phases and laying a solid foundation for future growth.
See More
